|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: THEM6 |
Gene summary for THEM6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | THEM6 | Gene ID | 51337 |
| Gene name | thioesterase superfamily member 6 | |
| Gene Alias | C8orf55 | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8WUY1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51337 | THEM6 | HCC2 | Human | Liver | HCC | 2.69e-15 | 2.63e+00 | 0.5341 |
| 51337 | THEM6 | Pt13.a | Human | Liver | HCC | 1.57e-05 | 1.17e-01 | 0.021 |
| 51337 | THEM6 | Pt13.b | Human | Liver | HCC | 1.76e-20 | 2.76e-01 | 0.0251 |
| 51337 | THEM6 | Pt14.a | Human | Liver | HCC | 3.55e-04 | 2.28e-01 | 0.0169 |
| 51337 | THEM6 | S014 | Human | Liver | HCC | 2.80e-51 | 1.37e+00 | 0.2254 |
| 51337 | THEM6 | S015 | Human | Liver | HCC | 2.31e-48 | 1.91e+00 | 0.2375 |
| 51337 | THEM6 | S016 | Human | Liver | HCC | 5.92e-45 | 1.29e+00 | 0.2243 |
| 51337 | THEM6 | S027 | Human | Liver | HCC | 8.87e-19 | 1.08e+00 | 0.2446 |
| 51337 | THEM6 | S028 | Human | Liver | HCC | 7.89e-43 | 1.32e+00 | 0.2503 |
| 51337 | THEM6 | S029 | Human | Liver | HCC | 7.94e-40 | 1.31e+00 | 0.2581 |
| 51337 | THEM6 | C04 | Human | Oral cavity | OSCC | 1.52e-16 | 8.02e-01 | 0.2633 |
| 51337 | THEM6 | C21 | Human | Oral cavity | OSCC | 6.42e-24 | 6.26e-01 | 0.2678 |
| 51337 | THEM6 | C30 | Human | Oral cavity | OSCC | 4.66e-11 | 6.14e-01 | 0.3055 |
| 51337 | THEM6 | C43 | Human | Oral cavity | OSCC | 5.92e-46 | 7.99e-01 | 0.1704 |
| 51337 | THEM6 | C46 | Human | Oral cavity | OSCC | 9.38e-24 | 5.05e-01 | 0.1673 |
| 51337 | THEM6 | C51 | Human | Oral cavity | OSCC | 4.17e-16 | 6.14e-01 | 0.2674 |
| 51337 | THEM6 | C57 | Human | Oral cavity | OSCC | 3.58e-09 | 3.60e-01 | 0.1679 |
| 51337 | THEM6 | C06 | Human | Oral cavity | OSCC | 1.55e-06 | 1.04e+00 | 0.2699 |
| 51337 | THEM6 | C08 | Human | Oral cavity | OSCC | 1.77e-29 | 5.33e-01 | 0.1919 |
| 51337 | THEM6 | LN22 | Human | Oral cavity | OSCC | 1.48e-11 | 1.35e+00 | 0.1733 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| THEM6 | SNV | Missense_Mutation | c.519N>T | p.Glu173Asp | p.E173D | Q8WUY1 | protein_coding | tolerated(0.23) | benign(0.04) | TCGA-AA-3972-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD | |
| THEM6 | SNV | Missense_Mutation | rs200343822 | c.535N>A | p.Ala179Thr | p.A179T | Q8WUY1 | protein_coding | tolerated(0.06) | benign(0.335) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| THEM6 | SNV | Missense_Mutation | rs764843549 | c.563A>G | p.Asn188Ser | p.N188S | Q8WUY1 | protein_coding | tolerated(0.14) | possibly_damaging(0.628) | TCGA-EO-A2CG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |